@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix hgnc: . @prefix proteinModification: . @prefix psimod: . @prefix Protein: . @prefix geneProductOf: . @prefix mesh: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 belv:variantOf hgnc:7797; a proteinModification:, psimod:00696 . sub:_2 geneProductOf: hgnc:7797; a Protein: . sub:_3 occursIn: mesh:D016676, species:9606; rdf:object sub:_2; rdf:predicate belv:directlyDecreases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:NFKBIA,pmod(P,S,32)) =| p(HGNC:NFKBIA)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "an increase in phosphorylated IkB (Serine 32) levels was observed after exposure to CS medium leading to IkB turnover. In contrast, stabilized IkB levels was demonstrated as macrophages pretreated with proteasome inhibitor, MG-132, for one hour before exposure to CS (Fig. 5A). "; prov:wasQuotedFrom pubmed:16620395 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:16620395; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:42.710+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }